12/19/2013 9:47:04 AM
GAINESVILLE, Fla.--(BUSINESS WIRE)--AGTC, a privately-held, clinical stage biotechnology company, announced today that the company has been awarded an additional $657,699 in funding under the Small Business Technology Transfer Program of the National Eye Institute (NEI), a division of the National Institutes of Health. This grant will supplement ongoing work under the $8.4 million grant AGTC was awarded by the NEI earlier this year and will support expansion of the company’s preclinical development work for AAV-CNGB3, a gene therapy treatment for achromatopsia. Funds will be used to conduct additional studies in an animal model of the disease using the species-specific version of the CNGB3 gene, which is expected to provide safety and efficacy results that better predict responses in human clinical trials.
Help employers find you! Check out all the jobs and post your resume.
comments powered by